From June 22 to 25, 2026, ETAP‑LAB will attend the BIO International Convention in San Diego, the world’s leading biotechnology event bringing together more than 20,000 industry leaders across biotech, pharma, and life sciences.
As part of the French delegation, alongside Business France Healthcare North America, ETAP‑LAB will take part in BIO Partnering™, the reference platform for one‑to‑one business meetings during the event.
👉 Learn more about the event: https://convention.bio.org/
Where innovation meets decision-making
The BIO International Convention is not just a scientific conference — it is where strategic decisions are made.
Over four days, biotech startups, pharma leaders, CROs, and investors gather to:
- initiate partnerships
- accelerate R&D programs
- secure funding and licensing deals
- move innovative therapies toward patients
For companies navigating the complexity of drug development, BIO is a unique opportunity to connect directly with the right partners at the right time. Meet ETAP-LAB this time!
Why meet ETAP‑LAB at BIO 2026?
At ETAP‑LAB, our objective at BIO is clear: help you move your therapeutic innovations forward with confidence.
We support all types of preclinical-stage projects, from early discovery to advanced translational studies, including in vitro lead optimization to non-GLP animal testing (POC studies, PK/PD modeling and non-regulatory safety pharmacology).
Whatever your range of therapeutic innovation: small molecules, antibodies & biotherapies, cell therapies, medical devices and nutraceuticals.
What you gain by meeting us
Whether you are:
- preparing an IND
- validating a candidate before fundraising
- or facing key go/no‑go decisions
We provide advice and expert services:
- robust, decision‑enabling data with high translational relevance
- optimized study designs to reduce experimental and regulatory risks
- fast, responsive support adapted to your timelines
- end-to-end capabilities, from in vitro to in vivo and advanced analyses
From early discovery to in vivo validation: a fully integrated approach
One of ETAP‑LAB’s key strengths lies in its transversal expertise.
For example, in neurodegenerative diseases such as Alzheimer’s:
- start with high‑content in vitro screening (human iPSC-derived models, primary cells)
- refine candidate selection with multiparametric analyses
- progress seamlessly toward in vivo studies, including advanced behavioral pharmacology
- complete your program with integrated biological analyses (e.g. immunohistochemistry)
Result: A consistent, reliable data package to support your development milestones and investor discussions.
New structure, clearer offer: discover our 4 specialized brands
BIO 2026 will also be the opportunity to introduce our new brand architecture and website.
To improve clarity and enhance your experience, we have organized our expertise into four dedicated service brands:
- BRAINXPLORE — Neurology / CNS
- SKINAXIS — Dermatology
- STROK@LLIANCE — Neurovascular / Stroke
- SYNCROSOME — Cardiology
All under one unified entity, ETAP‑LAB, as a trusted & renowned preclinical CRO.
What’s new for you
- clearer service positioning by therapeutic area
- easier navigation across our portfolio of models and technologies
- faster access to expert teams
- a more intuitive and efficient customer journey
Explore our new website now: https://www.etap-lab.com/en/
Meet us through BIO Partnering™
ETAP‑LAB will be available exclusively through BIO Partnering™ one‑to‑one meetings, and also at the French Pavilion.
👤 Nicolas Violle, CEO, will be on-site to discuss your projects.
You should meet us if you have an ongoing preclinical program and need a trusted CRO partner with strong scientific expertise.
📅 Request a meeting directly via the partnering platform (https://convention.bio.org/) or through our website (https://www.etap-lab.com/en/contact/).
Supported by our ecosystem
ETAP‑LAB’s participation in BIO 2026 is supported by:
- Eurobiomed, through its international development program, and the Région Sud Provence-Alpes-Côte d’Azur, providing financial support.
- Business France Healthcare North America, as part of the French delegation
This backing reflects the recognition of ETAP‑LAB’s expertise and its ambition to expand internationally.
Let’s accelerate your preclinical development
At BIO 2026, our goal is simple: help you reduce uncertainty, gain clarity, and move faster toward clinical development. We look forward to meeting you in San Diego.
In the meantime, feel free to subscribe to our NEW newsletter, which will be released in June 2026!
